当前位置:产品中心 > 抗体 > Biosimilar抗体 > 细胞因子 > Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)
Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)
产品简介

产品编号:GM-88056MAB

产品名称:Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)

目录价:询价

产品配图.jpg


规格货号

GM-88056MAB-1mg / 1 mg

GM-88056MAB-5mg / 5 mg

GM-88056MAB-25mg / 5 mg * 5 vials

GM-88056MAB-50mg / 50 mg

GM-88056MAB-100mg / 50 mg * 2 vials



产品简介

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Species Reactivity

Human

Clone

BMS-981164

Source/Isotype

Human IgG4(S228P), kappa

Application

Bioactivity-ELISA

Specificity

Detects IL-31

Gene

IL-31

Other Names

/

Gene ID

386653 (human)

Background

IL-31 is a cytokine belonging to the IL-6 family-related chemokine lineage, encoding a precursor protein that is secreted into an active form after splicing. It is regulated by inflammatory signals and barrier damage, etc. , the promoter region is regulated by STAT, NF-κb and other pathways, and there may be tissue-specific splice variants. IL-31 is mainly expressed in skin-associated immune cells (such as Th2 cells, mast cells, dendritic cell, etc.) and epithelial cells, with systemic baseline expression but higher in local inflammatory sites; It is closely related to inflammatory environment, barrier damage, infection and allergic reaction. Its function is to form a heterodimer with the receptor IL-31RA and co-receptor OSMR β, which activates Jak/STAT, MAPK and other signaling pathways, it promotes pro-inflammatory response, cell proliferation and differentiation, as well as neuro-immune coupling and itch signaling, and participates in pathological processes such as eczema/atopic dermatitis and chronic pruritus. In terms of drug development, targets can be IL-31 ontology, IL-31RA or OSMR β, and antibody drugs need to take into account cross-species differences, structure-function relationships, and coordinated regulation of local and systemic inflammation in the skin, and combined with biomarkers to achieve patient stratification treatment.

Formulation

Phosphate-buffered solution, pH 7.2-7.4.

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay


数据展示

image.png

image.png

image.png

当前位置:产品中心 > 抗体 > Biosimilar抗体 > Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)

Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)
产品简介

产品编号:GM-88056MAB

产品名称:Anti-IL-31 hIgG4 Reference Antibody (BMS-981164)

目录价:询价

产品配图.jpg


规格货号

GM-88056MAB-1mg / 1 mg

GM-88056MAB-5mg / 5 mg

GM-88056MAB-25mg / 5 mg * 5 vials

GM-88056MAB-50mg / 50 mg

GM-88056MAB-100mg / 50 mg * 2 vials



产品简介

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Species Reactivity

Human

Clone

BMS-981164

Source/Isotype

Human IgG4(S228P), kappa

Application

Bioactivity-ELISA

Specificity

Detects IL-31

Gene

IL-31

Other Names

/

Gene ID

386653 (human)

Background

IL-31 is a cytokine belonging to the IL-6 family-related chemokine lineage, encoding a precursor protein that is secreted into an active form after splicing. It is regulated by inflammatory signals and barrier damage, etc. , the promoter region is regulated by STAT, NF-κb and other pathways, and there may be tissue-specific splice variants. IL-31 is mainly expressed in skin-associated immune cells (such as Th2 cells, mast cells, dendritic cell, etc.) and epithelial cells, with systemic baseline expression but higher in local inflammatory sites; It is closely related to inflammatory environment, barrier damage, infection and allergic reaction. Its function is to form a heterodimer with the receptor IL-31RA and co-receptor OSMR β, which activates Jak/STAT, MAPK and other signaling pathways, it promotes pro-inflammatory response, cell proliferation and differentiation, as well as neuro-immune coupling and itch signaling, and participates in pathological processes such as eczema/atopic dermatitis and chronic pruritus. In terms of drug development, targets can be IL-31 ontology, IL-31RA or OSMR β, and antibody drugs need to take into account cross-species differences, structure-function relationships, and coordinated regulation of local and systemic inflammation in the skin, and combined with biomarkers to achieve patient stratification treatment.

Formulation

Phosphate-buffered solution, pH 7.2-7.4.

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay


数据展示

image.png

image.png

image.png

Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交